Impact of the COVID-19 pandemic on multidrug-resistant hospital-acquired bacterial infections

Bongiovanni, Marco; Barilaro, Giuseppe; Zanini, Umberto; Giuliani, G

doi:10.1016/j.jhin.2022.02.015

Cited by 16 publications

(14 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More and better data are needed to better understand the incidence of coinfections and the pathogens involved, as well as the impact of underlying risk factors on patients. Recent reports have described a high use of broad-spectrum antibiotics as a risk factor in the emergence of multidrug-resistant microorganisms, which often appear in critically ill COVID-19 patients (29)(30)(31).…”

Section: Impact Of Covid-19 On Antibiotic Prescriptionmentioning

confidence: 99%

Antimicrobial Resistance in the COVID-19 Landscape: Is There an Opportunity for Anti-Infective Antibodies and Antimicrobial Peptides?

et al. 2022

View full text Add to dashboard Cite

Although COVID-19 has captured most of the public health attention, antimicrobial resistance (AMR) has not disappeared. To prevent the escape of resistant microorganisms in animals or environmental reservoirs a “one health approach” is desirable. In this context of COVID-19, AMR has probably been affected by the inappropriate or over-use of antibiotics. The increased use of antimicrobials and biocides for disinfection may have enhanced the prevalence of AMR. Antibiotics have been used empirically in patients with COVID-19 to avoid or prevent bacterial coinfection or superinfections. On the other hand, the measures to prevent the transmission of COVID-19 could have reduced the risk of the emergence of multidrug-resistant microorganisms. Since we do not currently have a sterilizing vaccine against SARS-CoV-2, the virus may still multiply in the organism and new mutations may occur. As a consequence, there is a risk of the appearance of new variants. Nature-derived anti-infective agents, such as antibodies and antimicrobial peptides (AMPs), are very promising in the fight against infectious diseases, because they are less likely to develop resistance, even though further investigation is still required.

show abstract

Section: Impact Of Covid-19 On Antibiotic Prescriptionmentioning

confidence: 99%

Antimicrobial Resistance in the COVID-19 Landscape: Is There an Opportunity for Anti-Infective Antibodies and Antimicrobial Peptides?

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The incidence of MDR-GNB infections in critically ill COVID-19 patients in different regions of the world ranges between 3.4% to 46%. 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 COVID-19 patients admitted to the ICU also seem to be more susceptible to colonization by MDR. [16] …”

Section: Introductionmentioning

confidence: 99%

“…Studies have shown that mainly critically ill patients with COVID-19 have secondary infections, 6 , 7 , 8 , 9 , 10 a proportion of them caused by Multidrug-Resistant (MDR) Gram-Negative Bacteria (GNB). The incidence of MDR-GNB infections in critically ill COVID-19 patients in different regions of the world ranges between 3.4% to 46%.…”

Section: Introductionmentioning

confidence: 99%

The health facility as a risk factor for multidrug-resistant gram-negative bacteria in critically ill patients with COVID-19

Macedo

Santos²,

Silva

et al. 2022

Clinics

View full text Add to dashboard Cite

“…Multidrug-resistant (MDR) bacteria threaten health worldwide. During the COVID-19 outbreak, MDR infections spread rapidly and more severely in hospitalized patients due to the longer duration of antimicrobial therapy to manage respiratory complications 1 – 6 . The development of alternative treatments is an urgent issue owing to the increasing number of patients with challenging infectious strains.…”

Section: Introductionmentioning

confidence: 99%

Modification of the immune response by bacteriophages alters methicillin-resistant Staphylococcus aureus infection

Suda

Hanawa

Tanaka

et al. 2022

Sci Rep

View full text Add to dashboard Cite

There is an urgent need to develop phage therapies for multidrug-resistant bacterial infections. However, although bacteria have been shown to be susceptible to phage therapy, phage therapy is not sufficient in some cases. PhiMR003 is a methicillin-resistant Staphylococcus aureus phage previously isolated from sewage influent, and it has demonstrated high lytic activity and a broad host range to MRSA clinical isolates in vitro. To investigate the potential of phiMR003 for the treatment of MRSA infection, the effects of phiMR003 on immune responses in vivo were analysed using phiMR003-susceptible MRSA strains in a mouse wound infection model. Additionally, we assessed whether phiMR003 could affect the immune response to infection with a nonsusceptible MRSA strain. Interestingly, wounds infected with both susceptible and nonsusceptible MRSA strains treated with phiMR003 demonstrated decreased bacterial load, reduced inflammation and accelerated wound closure. Moreover, the infiltration of inflammatory cells in infected tissue was altered by phiMR003. While the effects of phiMR003 on inflammation and bacterial load disappeared with heat inactivation of phiMR003. Transcripts of proinflammatory cytokines induced by lipopolysaccharide were reduced in mouse peritoneal macrophages. These results show that the immune modulation occurring as a response to the phage itself improves the clinical outcomes of phage therapy.

show abstract

Impact of the COVID-19 pandemic on multidrug-resistant hospital-acquired bacterial infections

Cited by 16 publications

References 8 publications

Antimicrobial Resistance in the COVID-19 Landscape: Is There an Opportunity for Anti-Infective Antibodies and Antimicrobial Peptides?

Antimicrobial Resistance in the COVID-19 Landscape: Is There an Opportunity for Anti-Infective Antibodies and Antimicrobial Peptides?

The health facility as a risk factor for multidrug-resistant gram-negative bacteria in critically ill patients with COVID-19

Modification of the immune response by bacteriophages alters methicillin-resistant Staphylococcus aureus infection

Contact Info

Product

Resources

About